Complete title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)
Research Study Number | 9876 |
Principal Investigator | David Maloney, MD, PhD |
Phase | II |
Other eligibility criteria may apply.
Research Study Number | 9876 |
Contact | Seattle Cancer Care Alliance Intake Office |
Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Immunoproliferative Disorders; Lymphoma, B-Cell; Lymphoma, Follicular; Immune System Diseases; Lymphoma, Marginal Zone; Hematologic Diseases; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Indolent Non-Hodgkin
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.